AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03429543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 1 film-coated tablet Linagliptin once daily, until end of treatment.
Study NCT03429543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 1 film-coated tablet of Empagliflozin once daily, until end of treatment.
Study NCT01008124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberatory Maneuver
Description: 3 cycles of the liberatory maneuver initial session.
Study NCT01008124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo maneuver
Description: 3 cycles placebo maneuver initial session.
Study NCT03854539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transdermal Vagus Nerve Stimulation
Description: intermittent transdermal stimulation of the aurical vagus
Study NCT03854539 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transdermal Vagus Nerve Stimulation
Description: intermittent transdermal stimulation of the aurical vagus
Study NCT00594594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus GR-1 and RC-14
Description: Two capsules of Lactobacillus GR-1 and RC-14 daily for 12 months
Study NCT04511065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Newsletter using a virtual mode of delivery
Description: Newsletter creation where topics in the newsletter are chosen by participants in the intervention group.
Study NCT00094107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib [AG-013736]
Description: VEGFR \[vascular endothelial growth factor Receptor\] and PDGFR \[Platelet-Derived Growth Factor Receptor\] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.
Study NCT00870298 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trimethoprim/Sulfamethoxazole and Warfarin
Study NCT00870298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole and Warfarin
Study NCT00924404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: 5% solution for sinus rinse
Study NCT00924404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: saline for sinus rinse
Study NCT00454181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Description: 500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks
Study NCT00454181 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks
Study NCT01843270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: actual body weight based size
Description: According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
Study NCT01843270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ideal body weight based size
Description: According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
Study NCT01205126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
Study NCT01205126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
Study NCT03264976 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hematological examination, ophthalmic examination
Description: Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP)；Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
Study NCT01924559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope
Study NCT01924559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supraglottic Airway
Study NCT01822080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo once daily by mouth
Study NCT03057665 — intervention group
Intervention type: DEVICE
Intervention: Atomic Biomagnetometer
Description: Measure magnetic field of fetal heartbeat
Study NCT00640315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521) 1.0 mg
Description: 1.0 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
Study NCT00640315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521) 2.5 mg
Description: 2.5 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
Study NCT00922740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
Study NCT00922740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
Study NCT02641158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: After screening HCV antibody positive, participants will receive an appointment and reminder card to return for their HCV RNA results. If HCV RNA positive, study staff will attempt to make an appointment for the participant's next step in the HCV continuum. If a participant attends the next step visit, the participant would be subject to whatever is the local standard of care at that clinic/agency from that point forward.
Study NCT02641158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Facilitation Group
Description: The same will occur for intervention participants, yet an HCV care facilitator will motivate them to return for their HCV RNA results; appointment reminders will be made prior to the next step visit; follow-up contact will be made for missed appointments; and the HCV care facilitator will coordinate and link the participant to available community resources (e.g., mental health, housing agencies) by scheduling appointments, arranging transportation, and helping to complete any clinic registration (or other) paperwork that agencies may require to access services.
Study NCT00610246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.
Study NCT00696787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Sustained Release (DVS SR)
Study NCT00696787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica® (Pregabalin)
Study NCT00696787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01971047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Insulin
Description: Group 1 Treatment Arm,Follow dosing for BG >180 per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG>240 mg/dl after 2 hours of initial dose
Study NCT01971047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Description: Group 2 treatment arm. Follow dosing for Blood glucose > 180, per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG>240 mg/dl after 2 hours of initial dose
Study NCT03645863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6548
Description: Oral tablet
Study NCT03645863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron supplement A
Description: Oral tablet
Study NCT03645863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron supplement B
Description: Oral tablet
Study NCT03645863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron supplement C
Description: Oral tablet
Study NCT03645863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron supplement D
Description: Oral tablet
Study NCT04465981 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sampling
Description: Test is to validate the utility of INanoBio's automated protein arrays in detecting antibodies against SARS-CoV-2 proteins.
Study NCT03892018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oraxol
Description: Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
Study NCT04486365 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bifocal bone transport.
Description: The bifocal approach is a single osteotomy to create one transported bone segment between the osteotomy and the defect.
Study NCT04486365 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trifocal bone transport
Description: The trifocal approach is two osteotomies creating two separate transported bone segments.
Study NCT03503695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sterile acupuncture semi-permanent (ASP) gold needles
Study NCT00996489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coaptite®
Description: Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
Study NCT01473407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira
Description: Variable dose
Study NCT01473407 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Epogen (Amgen)
Description: Variable dose
Study NCT00679133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD265
Description: Oral daily administration; 7 days on / 7 days off
Study NCT05229536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine
Description: Group 1: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.
Study NCT05229536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine
Description: Group 2: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.
Study NCT02754765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Study NCT02754765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Study NCT02754765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Study NCT02754765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Study NCT02754765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Study NCT02754765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Study NCT02754765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Study NCT02754765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control arm MDR-TB regimen, consistent with WHO guidelines
Description: Control arm MDR-TB regimen, consistent WHO guidelines
Study NCT00455156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)
Description: 150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
Study NCT02802904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet: Palm olein IV64
Description: Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat Palm Olein IV64 which was incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
Study NCT02802904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet: Cocoa butter
Description: Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat cocoa butter which was incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
Study NCT02802904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet: Virgin olive oil
Description: Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat virgin olive oil which incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
Study NCT01573104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proteomic assay
Description: Urine will be taken for proteomic assay at baseline, day 1 and day 2
Study NCT01573104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Point of care testing of blood for NGAL/BNP at baseline, day 1 and day 2
Study NCT01573104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker sampling
Description: Urine will be taken at baseline and day 1, day 2 for evaluation of renal biomarkers at later date
Study NCT02453555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin
Study NCT02453555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Study NCT02453555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin placebo + linagliptin placebo low dose
Description: Matching placebo empagliflozin + linagliptin
Study NCT02453555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin placebo + linagliptin placebo low dose
Description: Matching placebo empagliflozin + linagliptin
Study NCT02453555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin + linagliptin low dose
Description: tablet
Study NCT02453555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin + linagliptin low dose
Description: tablet
Study NCT02453555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin placebo
Description: Matching placebo linagliptin
Study NCT02453555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin placebo
Description: Matching placebo linagliptin
Study NCT02453555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin + linagliptin high dose
Description: tablet
Study NCT02453555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin + linagliptin high dose
Description: tablet
Study NCT02453555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empa + lina highdose placebo
Study NCT02453555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empa + lina highdose placebo
Study NCT01008085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stentys coronary stent
Description: Self-expanding Nitinol stent
Study NCT01008085 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon-expandable stent
Description: VISION/Driver
Study NCT00136305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pictorial asthma action plan
Study NCT00136305 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written asthma action plan
Study NCT02680951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Administered orally on a once daily schedule based on the dose level assigned to the patient at enrollment (60, 80, or 100mg/m2/day). Patients may adjust the time they take dasatinib as long as they take the drug approximately every 24 hours
Study NCT01767623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemurafenib
Description: Vemurafenib orally BID 960 or 720 mg.
Study NCT01767623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib orally BID 960 or 720 mg.
Study NCT02540993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: Oral tablet; starting dose at 10 mg for subjects with an eGFR between 25 to \< 60 mL/min/1.73m² at the Screening Visit; starting dose at 20 mg for subjects with an eGFR ≥ 60 mL/min/1.73m² at the Screening Visit; dose could be up-titrated from Month 1 onwards or down-titrated at any time during the study; once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
Study NCT02680951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the fludarabine dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30
Study NCT02680951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2000 mg/m2/dose intravenous infusion over 1 to 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the cytarabine dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30
Study NCT03295253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous adipose tissue harvesting/grafting using Lipogems
Description: Adipose tissue harvesting and grafting in the urethra using fat micro-fragmentation and processing device Lipogems
Study NCT00967993 — intervention group
Intervention type: DRUG
Intervention: ferric citrate
Description: KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate
Study NCT00493584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention
Description: Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
Study NCT02540993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
Study NCT02974569 — intervention group
Intervention type: DEVICE
Intervention: Computer Symptom Capture Tool
Description: C-SCAT is an investigator developed app that is delivered via an iPad. The original CSCAT included the 30 symptoms from the Memorial Symptom Assessment Scale. The recently updated version includes two additional symptoms feeling bloated and sexual dysfunction that are included in the adult version of the MSAS.21 These symptoms were added based on feedback from the initial AYA sample of 13-29 year olds and in consideration of the developmental perspectives of the AYA population.The CSCAT allows the user to create an image of his or her symptom experience.
Study NCT00079677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg/day
Description: Armodafinil 150 mg once daily in the morning
Study NCT00079677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets once daily
Study NCT04462939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elevit Breastfeeding & Postnatal Care
Description: Multi-micronutrients, lutein and DHA soft gel capsules; one capsule daily, oral
Study NCT04462939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active ingredients except of 225 μg iodine; One capsule daily, oral